Repositorio Dspace

Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: Results from the VISIONARY Study Population in Spain

Mostrar el registro sencillo del ítem

dc.contributor.author García-Medina, José-Javier
dc.contributor.author Benítez-del-Castillo, Javier
dc.contributor.author Rodríguez-Agirretxe, Inaki
dc.contributor.author López-López, Fernando
dc.contributor.author Moreno-Valladares, Antonio
dc.date.accessioned 2025-11-19T15:37:24Z
dc.date.available 2025-11-19T15:37:24Z
dc.date.issued 2022-04-01
dc.identifier.citation Garcia-Medina JJ, Benitez-del-Castillo J, Rodríguez-Agirretxe I, Lopez-Lopez F, Moreno-Valladares A, the VISIONARY Study Group (Spain), et al. Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: Results from the VISIONARY Study Population in Spain. Journal of Ocular Pharmacology and Therapeutics. 1 de abril de 2022;38(3):252-60.
dc.identifier.issn 1080-7683
dc.identifier.uri https://sms.carm.es/ricsmur/handle/123456789/21321
dc.description.abstract Purpose: Data are presented from ophthalmology clinics in Spain participating in the VISIONARY study, examining the effectiveness, tolerability, and safety of the preservative-free tafluprost (0.0015%) and timolol (0.5%) fixed-dose combination (PF tafluprost/timolol FC) in the treatment of OAG and OHT. Methods: An observational, multicenter prospective study examined treatment outcomes following a switch to PF tafluprost/timolol FC in adult OAG/OHT patients demonstrating insufficient response to beta-blocker or prostaglandin analog (PGA) monotherapy. Primary end point was mean change in intraocular pressure (IOP) from baseline at month 6. Changes in the severity of ocular signs and symptoms were also assessed. Results: Overall, 92 patients (51.1% female) were included. Mean (standard deviation) age was 68.3 (12.1) years. Mean IOP was reduced from 21.9 mmHg at baseline to 16.7 mmHg at month 6 (22.3% decrease; P < 0.0001). Significant IOP reductions were observed at weeks 4 and 12 (P < 0.0001). Baseline PGA and beta-blocker users demonstrated mean month 6 IOP reductions of 5.5 mmHg (23.5%; P < 0.001) and 3.5 mmHg (14.6%; P = 0.029), respectively. Severity of conjunctival hyperemia, dry eye, irritation, itching, foreign body sensation, and eye pain was significantly reduced. Three treatment-related adverse events were reported, all were nonserious and mild/moderate in severity. Conclusion: In real-world clinical practice, PF tafluprost/timolol FC treatment provided significant IOP reductions over 6 months and was well tolerated among OAG/OHT patients showing poor response to PGA or beta-blocker monotherapy. IOP-lowering efficacy and improvements in ocular signs and symptoms were evident from week 4 and maintained over the 6-month study period. Trial Registration: European Union electronic Register of Post-Authorisation Studies (EU PAS) register number EUPAS22204.
dc.language.iso eng
dc.publisher MARY ANN LIEBERT, INC
dc.rights Atribución-NoComercial-SinDerivadas 3.0 España
dc.rights.uri http://creativecommons.org/licenses/by-nc-nd/3.0/es *
dc.subject.mesh Adult
dc.subject.mesh Aged
dc.subject.mesh Antihypertensive Agents/adverse effects
dc.subject.mesh Drug Combinations
dc.subject.mesh Female
dc.subject.mesh Glaucoma/drug therapy
dc.subject.mesh Glaucoma, Open-Angle/drug therapy
dc.subject.mesh Humans
dc.subject.mesh Intraocular Pressure
dc.subject.mesh Male
dc.subject.mesh Ocular Hypertension/chemically induced/drug therapy
dc.subject.mesh Preservatives, Pharmaceutical/adverse effects
dc.subject.mesh Prospective Studies
dc.subject.mesh Prostaglandins/therapeutic use
dc.subject.mesh Prostaglandins A/therapeutic use
dc.subject.mesh Prostaglandins F
dc.subject.mesh Prostaglandins, Synthetic/therapeutic use
dc.subject.mesh Spain
dc.subject.mesh Timolol/adverse effects
dc.title Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: Results from the VISIONARY Study Population in Spain
dc.type info:eu-repo/semantics/article
dc.identifier.pmid 35230148
dc.relation.publisherversion https://www.liebertpub.com/doi/10.1089/jop.2021.0099
dc.identifier.doi 10.1089/jop.2021.0099
dc.journal.title Journal of Ocular Pharmacology and Therapeutics
dc.identifier.essn 1557-7732


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución-NoComercial-SinDerivadas 3.0 España Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución-NoComercial-SinDerivadas 3.0 España

Buscar en DSpace


Búsqueda avanzada

Listar

Mi cuenta